Contact

• workQueen's Medical Centre
  Nottingham
  NG7 2UH
  UK
• workExt 31072
• Rob.Scott@nottingham.ac.uk
• https://nddcbru.org.uk/

Biography

NIHR Academic Clinical Lecturer in Gastroenterology and Hepatology

Expertise Summary

Clinical trials in advanced chronic liver disease of any aetiology. My particular interest is risk stratifying patients such as using Magnetic Resonance Imaging (MRI) to characterise patients with chronic liver disease and evaluate the effect of interventions. Specialist interests are in;

• Compensated advanced chronic liver disease
• Portal hypertension
• Multi-organ components of the hyperdynamic circulation
• Surgery in patients with cirrhosis
• Gut permeability
• Infections in cirrhosis
• Hepatocellular carcinoma (HCC) detection and screening
• Involving patients and other stakeholders in the design and outputs of clinical research

Research Summary

Can quantitative MRI evaluate treatment response to beta-blockers? Can we accurately predict and reduce risk of non-liver surgery? Can we predict clinically important outcomes in those with… read more

Recent Publications

• SCOTT, R. and BOWLING, T.E., 2015. Enteral tube feeding in adults Journal of the Royal College of Physicians of Edinburgh. 45(1), 49-54
• SCOTT R and GUHA IN, 2014. Non-invasive monitoring of liver fibrosis. British medical bulletin. 112(1), 97-106
• SCOTT, R. A., AUSTIN, A. S., KOLHE, N. V., MCINTYRE, C. W. and SELBY, N. M., 2013. Acute kidney injury is independently associated with death in patients with cirrhosis: Frontline Gastroenterol Frontline Gastroenterol. 4(3), 191-197
• SCOTT, R., WILLIAMS, M., LAWSON, A., AUSTIN, A. and FREEMAN, J., 2012. Service provision for liver disease in the UK: A national questionnaire-based survey Clinical Medicine, Journal of the Royal College of Physicians of London. 12(2), 114-118

• View all publications

Current Research

• Can quantitative MRI evaluate treatment response to beta-blockers?
• Can we accurately predict and reduce risk of non-liver surgery?
• Can we predict clinically important outcomes in those with advcanced chronic liver disease?
• Can we detect and screen for Hepatocellular carcinoma (HCC) better?
• Does gut permeability predict outcomes in patients with advanced chronic liver disease?
• Can we use routine clinical data to risk stratify advanced chronic liver disease?
• Are there common mechanisms in mutli-morbidity fibrosis?

• SCOTT, R. and BOWLING, T.E., 2015. Enteral tube feeding in adults Journal of the Royal College of Physicians of Edinburgh. 45(1), 49-54
• SCOTT R and GUHA IN, 2014. Non-invasive monitoring of liver fibrosis. British medical bulletin. 112(1), 97-106
• SCOTT, R. A., AUSTIN, A. S., KOLHE, N. V., MCINTYRE, C. W. and SELBY, N. M., 2013. Acute kidney injury is independently associated with death in patients with cirrhosis: Frontline Gastroenterol Frontline Gastroenterol. 4(3), 191-197
• SCOTT, R., WILLIAMS, M., LAWSON, A., AUSTIN, A. and FREEMAN, J., 2012. Service provision for liver disease in the UK: A national questionnaire-based survey Clinical Medicine, Journal of the Royal College of Physicians of London. 12(2), 114-118
• RYE, K., SCOTT, R., MORTIMORE, G., LAWSON, A., AUSTIN, A. and FREEMAN, J., 2012. Towards noninvasive detection of oesophageal varices: Int J Hepatol Int J Hepatol. 2012, 343591